Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

axogen inc - AXGN

AXGN

Close Chg Chg %
32.64 0.16 0.49%

Closed Market

32.80

+0.16 (0.49%)

Volume: 414.14K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Trade Now

Company Overview: axogen inc - AXGN

AXGN Key Data

Open

$32.63

 Day Range

32.03 - 33.00

52 Week Range

9.22 - 34.24

 Market Cap

$1.51B

Shares Outstanding

46.12M

 Public Float

44.88M

Beta

1.06

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.05

Yield

0.00%

 Dividend

$1.00

EX-DIVIDEND DATE

Jan 27, 2010

 SHORT INTEREST

N/A

AVERAGE VOLUME

909.76K

  

AXGN Performance

1 Week
 
 2.56%
 
1 Month
 
 14.49%
 
3 Months
 
 91.14%
 
1 Year
 
 96.88%
 
5 Years
 
 85.21%
 

AXGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About axogen inc - AXGN

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

AXGN At a Glance

Axogen, Inc.
13631 Progress Boulevard
Alachua, Florida 32615
Phone 1-386-462-6800 Revenue 187.34M
Industry Medical Specialties Net Income -9,964,000.00
Sector Health Technology 2024 Sales Growth 17.814%
Fiscal Year-end 12 / 2025 Employees 452
View SEC Filings

AXGN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.893
Price to Book Ratio 7.002
Price to Cash Flow Ratio 160.83
Enterprise Value to EBITDA 166.719
Enterprise Value to Sales 4.049
Total Debt to Enterprise Value 0.091

AXGN Efficiency

Revenue/Employee 414,464.602
Income Per Employee -22,044.248
Receivables Turnover 7.772
Total Asset Turnover 0.935

AXGN Liquidity

Current Ratio 3.241
Quick Ratio 2.157
Cash Ratio 1.29

AXGN Profitability

Gross Margin 75.787
Operating Margin -1.755
Pretax Margin -5.319
Net Margin -5.319
Return on Assets -4.975
Return on Equity -9.985
Return on Total Capital -5.773
Return on Invested Capital -5.966

AXGN Capital Structure

Total Debt to Total Equity 66.103
Total Debt to Total Capital 39.797
Total Debt to Total Assets 33.715
Long-Term Debt to Equity 64.208
Long-Term Debt to Total Capital 38.656
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Axogen Inc - AXGN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
127.36M 138.58M 159.01M 187.34M
Sales Growth
+13.41% +8.81% +14.74% +17.81%
Cost of Goods Sold (COGS) incl D&A
22.93M 24.15M 31.14M 45.36M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.74M 4.85M 5.55M 7.84M
Depreciation
4.54M 4.59M 5.28M 7.57M
Amortization of Intangibles
202.00K 265.00K 273.00K 267.00K
COGS Growth
+6.26% +5.30% +28.95% +45.68%
Gross Income
104.43M 114.44M 127.87M 141.98M
Gross Income Growth
+15.11% +9.59% +11.74% +11.03%
Gross Profit Margin
+81.99% +82.58% +80.42% +75.79%
2021 2022 2023 2024 5-year trend
SG&A Expense
129.84M 144.14M 149.34M 145.26M
Research & Development
24.18M 27.16M 28.33M 27.77M
Other SG&A
105.67M 116.99M 121.00M 117.50M
SGA Growth
+14.00% +11.01% +3.60% -2.73%
Other Operating Expense
- - - -
-
Unusual Expense
28.00K (1.04M) (1.53M) (587.00K)
EBIT after Unusual Expense
(25.44M) (28.66M) (19.93M) (2.70M)
Non Operating Income/Expense
(185.00K) 339.00K 1.05M 942.00K
Non-Operating Interest Income
93.00K 569.00K 1.49M 1.14M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.36M 624.00K 2.83M 8.21M
Interest Expense Growth
+28.65% -53.98% +354.33% +189.45%
Gross Interest Expense
1.36M 6.78M 8.12M 8.21M
Interest Capitalized
- - 6.16M 5.29M
-
Pretax Income
(26.98M) (28.95M) (21.72M) (9.96M)
Pretax Income Growth
-13.45% -7.27% +24.98% +54.12%
Pretax Margin
-21.19% -20.89% -13.66% -5.32%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(26.98M) (28.95M) (21.72M) (9.96M)
Minority Interest Expense
- - - -
-
Net Income
(26.98M) (28.95M) (21.72M) (9.96M)
Net Income Growth
-13.45% -7.27% +24.98% +54.12%
Net Margin Growth
-21.19% -20.89% -13.66% -5.32%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(26.98M) (28.95M) (21.72M) (9.96M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(26.98M) (28.95M) (21.72M) (9.96M)
EPS (Basic)
-0.6547 -0.6879 -0.5064 -0.2251
EPS (Basic) Growth
-10.02% -5.07% +26.38% +55.55%
Basic Shares Outstanding
41.22M 42.08M 42.88M 44.26M
EPS (Diluted)
-0.6547 -0.6879 -0.5064 -0.2251
EPS (Diluted) Growth
-10.02% -5.07% +26.38% +55.55%
Diluted Shares Outstanding
41.22M 42.08M 42.88M 44.26M
EBITDA
(20.68M) (24.85M) (15.91M) 4.55M
EBITDA Growth
-4.83% -20.21% +35.99% +128.60%
EBITDA Margin
-16.23% -17.93% -10.00% +2.43%

Snapshot

Average Recommendation BUY Average Target Price 35.70
Number of Ratings 10 Current Quarters Estimate 0.057
FY Report Date 12 / 2025 Current Year's Estimate 0.29
Last Quarter’s Earnings 0.12 Median PE on CY Estimate N/A
Year Ago Earnings 0.13 Next Fiscal Year Estimate 0.484
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 6 7 7
Mean Estimate 0.06 0.07 0.29 0.48
High Estimates 0.10 0.10 0.35 0.63
Low Estimate 0.03 0.01 0.27 0.41
Coefficient of Variance 43.71 53.07 10.53 16.17

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Axogen Inc - AXGN

Date Name Shares Transaction Value
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer 203,361 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer 209,723 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer 232,873 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer 217,762 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.5 per share 3,810,835.00
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer 6,363 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Erick Wayne DeVinney Chief Innovation Officer 23,150 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Amy A. McBride-Wendell Director 97,899 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.02 per share 1,959,937.98
Mar 6, 2025 Marc A. Began EVP & General Counsel 24,186 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Marc A. Began EVP & General Counsel 18,285 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.36 per share 335,712.60
Mar 6, 2025 Marc A. Began EVP & General Counsel 22,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Jens Schroeder Kemp Chief Marketing Officer 27,683 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.36 per share 508,259.88
Mar 6, 2025 Jens Schroeder Kemp Chief Marketing Officer 31,686 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.49 per share 522,502.14

Axogen Inc in the News